Table IV.
No. | Sex | Age, years | Diagnosis | PET/CT manifestation | SUVmax | T/B cell ratio | Therapeutic regimen | Efficacy |
---|---|---|---|---|---|---|---|---|
1 | Male | 24 | CAA | Hypometabolism complicated by focal hyperproliferation | 6.10 | 5.62 | CsA | CR |
2 | Male | 50 | CAA | Hypometabolism complicated by focal hyperproliferation | 8.80 | 13.86 | CsA | PR |
3 | Female | 59 | CAA | Diffuse hypometabolism | 1.80 | 16.85 | CsA | PR |
4 | Female | 60 | CAA | Hypometabolism complicated by focal hyperproliferation | 2.90 | 2.22 | CsA | NC |
5 | Male | 23 | CAA | Hypometabolism complicated by focal hyperproliferation | 3.20 | 8.74 | CsA | PR |
6 | Female | 54 | CAA | Hypometabolism complicated by focal hyperproliferation | 2.20 | 7.61 | CsA | PR |
7 | Female | 34 | SAA | Normal metabolism | 2.00 | 3.02 | ATG | PR |
8 | Male | 14 | SAA | Hypometabolism complicated by focal hyperproliferation | 2.50 | 2.53 | ATG | PR |
9 | Male | 27 | SAA | Hypometabolism complicated by focal hyperproliferation | 2.70 | 5.62 | ATG | CR |
10 | Female | 75 | SAA | Diffuse hypometabolism | 1.10 | 3.07 | CsA | CR |
11 | Female | 26 | SAA | Hypometabolism complicated by focal hyperproliferation | 3.10 | 8.99 | CsA | NC |
12 | Male | 36 | SAA | Hypometabolism complicated by focal hyperproliferation | 5.00 | 5.86 | CsA | NC |
13 | Male | 48 | SAA | Diffuse hypometabolism | 1.50 | 5.28 | CsA | PR |
14 | Male | 13 | SAA | Diffuse hypometabolism | 1.3 | 10.51 | Allo-BMT | CR |
15 | Female | 43 | SAA | Hypometabolism complicated by focal hyperproliferation | 4.5 | 7.43 | Compatriots | CR |
16 | Male | 43 | SAA | Hypometabolism complicated by focal hyperproliferation | 2.8 | 3.66 | Compatriots | CR |
17 | Male | 43 | SAA | Hypometabolism complicated by focal hyperproliferation | 3.0 | 7.22 | Compatriots | CR |
18 | Male | 37 | SAA | Hypometabolism complicated by focal hyperproliferation | 3.0 | 16.75 | Compatriots | CR |
CAA, chronic aplastic anemia; SAA, severe aplastic anemia; PET/CT, positron emission tomography/computed tomography; SUVmax, maximum standardized uptake values; T/B cell ratio, ratio between T lymphocytes and B lymphocytes; CsA, ciclosporin A; Allo-BMT, allogeneic bone marrow transplantation from a human leucocyte antigen-identical sibling donor; CR, complete remission; PR, partial remission; NC, no change.